Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
glucocorticoids + inebilizumab
- Development stage
- Unknown
- Lead developer
- Amgen
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Glucocorticoids + inebilizumab is a combination therapy being evaluated for the treatment of neuromyelitis optica spectrum disorder (NMOSD). Inebilizumab is a humanized monoclonal antibody that targets CD19, a cell surface antigen present on B cells, including plasmablasts and plasma cells, leading to their depletion. Glucocorticoids, such as prednisone, are steroid hormones used for their potent anti-inflammatory and immunosuppressive effects. In the context of the STARGlu-NMO trial conducted by Tianjin Medical University General Hospital, this combination is studied to determine the optimal tapering strategy for oral glucocorticoids (slow vs. rapid) following the initiation of inebilizumab to prevent disease relapses in AQP4-IgG-positive patients.
- Brand names
- Uplizna
- Other names
- STARGlu-NMO
02
Targets
CD19 (B lymphocyte antigen CD19)GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on glucocorticoids + inebilizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on glucocorticoids + inebilizumab.